It's a hit: Eisai springs 'major surprise' with phase 3 win for Biogen-partnered Alzheimer's drug

By Nick Paul Taylor,Gabrielle Masson

Eisai’s phase 3 clinical trial of Biogen-partnered Alzheimer’s disease candidate lecanemab has hit its primary and key secondary endpoints. The result, which analysts called a “major surprise,” gives a big boost to the partners as they head toward an accelerated approval decision in January.